导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.01% | 3050/4773 |
| 近一周 | -2.30% | 1720/5462 |
| 近一月 | -4.52% | 2535/5421 |
| 近一季 | -8.25% | 2748/5209 |
| 近半年 | -3.58% | 2251/4920 |
| 近一年 | -0.44% | 2727/4366 |
| 近两年 | 42.11% | 1787/2954 |
| 近三年 | 23.93% | 1327/2253 |
| 成立以来 | 3.82% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.12% 3530/4961 |
12.46% 2177/5312 |
- - |
- - |
| 2025 | 19.04% 2256/4813 |
-1.23% 2617/3635 |
2.04% 1927/4076 |
18.21% 2337/4524 |
-0.08% 2345/4813 |
| 2024 | 15.35% 940/3463 |
2.51% 761/2808 |
-1.16% 955/3014 |
16.78% 1353/3129 |
-2.52% 2116/3463 |
| 2023 | -9.06% 1095/2656 |
3.96% 1084/2280 |
-4.02% 1014/2385 |
-2.64% 709/2515 |
-6.39% 1747/2655 |
| 2022 | -20.14% 939/2207 |
-14.30% 932/1919 |
6.85% 591/2016 |
-14.14% 1031/2113 |
1.56% 1223/2208 |
| 2021 | -5.57% 978/1822 |
-3.33% 802/1255 |
3.86% 948/1330 |
-6.67% 977/1466 |
0.77% 1062/1822 |
| 2020 | - - |
- - |
- - |
- - |
9.62% 627/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 兴业沪深300ETF VS. 长安沪深300非周期A(740101) |